Combined treatment of intestinal dysbiosis in patients with chronic hepatitis c on the background of obesity
1
UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE
Publication date: 2026-05-29
Wiadomości Lekarskie 2026;(5):936-944
KEYWORDS
ABSTRACT
Introduction:
Aim: To study the effectiveness of ursodeoxycholic acid use in the combined treatment of intestinal dysbiosis in patients with chronic Hepatitis C associated with obesity.
Material and Methods:
84 patients with CHC were examined. All patients underwent a microbiological study of stool, the levels of cytokine profile indicators were determined and the psychological status and the quality of life were assessed. Two groups were formed: 1 gr (n=40) – received LA-5 and BB-12 1 gtt. x TID and 2 gr (n=44) - LA-5 + BB-12 + UDCA 500 mg qhs for 1 month.
Results:
As a result of simultaneous administration of LA-5 + BB-12 + UDCA in the above-mentioned doses, in 93.2% of patients with CHC an normalization of the act of defecation and the disappearance of symptoms of intestinal dysbiosis were found. In patients taking only LA-5 and BB-12, the above-mentioned positive changes were observed in 62.5%.
Conclusions:
It was found that the additional prescription of UDCA in combination with a probiotic not only contributes to the restoration of colon microbiocenosis, but also improves the course of CHС, and increases the quality of life of patients.
Aim: To study the effectiveness of ursodeoxycholic acid use in the combined treatment of intestinal dysbiosis in patients with chronic Hepatitis C associated with obesity.
Material and Methods:
84 patients with CHC were examined. All patients underwent a microbiological study of stool, the levels of cytokine profile indicators were determined and the psychological status and the quality of life were assessed. Two groups were formed: 1 gr (n=40) – received LA-5 and BB-12 1 gtt. x TID and 2 gr (n=44) - LA-5 + BB-12 + UDCA 500 mg qhs for 1 month.
Results:
As a result of simultaneous administration of LA-5 + BB-12 + UDCA in the above-mentioned doses, in 93.2% of patients with CHC an normalization of the act of defecation and the disappearance of symptoms of intestinal dysbiosis were found. In patients taking only LA-5 and BB-12, the above-mentioned positive changes were observed in 62.5%.
Conclusions:
It was found that the additional prescription of UDCA in combination with a probiotic not only contributes to the restoration of colon microbiocenosis, but also improves the course of CHС, and increases the quality of life of patients.
Share
RELATED ARTICLE
| eISSN: | 2719-342X |
| ISSN: | 0043-5147 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
